Associate
Alice is an associate in the intellectual property team, specialising in the protection and exploitation of intellectual property rights with a focus on advising clients in the life sciences and healthcare, and technology sectors.
Language - English
Jurisdiction - England & Wales
Alice has particular experience in transactions relating to the development, commercialisation and transfer of intellectual property, including R&D, collaboration, and licensing arrangements. With a background in Natural Sciences, she has a strong interest in the life sciences and healthcare sector. In addition, her work with technology clients has given her a particular insight and interest into the digital healthcare space, including AI and other disruptive technologies.
Alice also frequently supports corporate finance colleagues in relation to the intellectual property aspects of corporate transactions.
Dr. Falk Pharma GmbH
Advised Dr. Falk Pharma GmbH, a German multi-national pharmaceutical company, on the IP aspects of its acquisition of Kynos Therapeutics Ltd, a clinical stage biopharmaceutical company focusing on the development of novel treatments for patients suffering from acute and chronic inflammatory diseases. This involved drafting and negotiating a patent assignment and licence agreement and a further option licence agreement.
Clinical-stage biopharmaceutical company
Advising a clinical-stage biopharmaceutical company developing a novel class of medicines in relation to the negotiation of a collaboration and licence arrangement with a clinical-stage radiopharmaceutical biotechnology company.
Clinical-stage biotechnology company
Advising AIM listed clinical-stage biotechnology company which is developing novel cancer immunotherapies in relation to complex series of licensing and related arrangements, an agreement with UK-based University, and a research and collaboration agreement with another clinical stage biotechnology company.
Large global pharmaceutical company
Advising a large global pharmaceutical company in relation to a collaboration agreement for the development and commercialisation of a combination regimen for the treatment of HIV.
S&P Global
Advised on the IP aspects of S&P Global's acquisition of TeraHelix Ltd, a financial technology firm specialising in advanced data modelling, linking, and reconciliation services, leveraging AI technology.
Iluma Alliance
Advised on the IP aspects of Iluma Alliance's acquisition of Anitox Group, a global developer and manufacturer of antimicrobial preservatives for animal feed performance additives, operating across the US, Europe, Africa, Asia Pacific and Latin America.
Cityfleet Network
Advised on the IP aspects of Cityfleet Network's acquisition of Addison Lee.
